Clinical research blog
Explore our blog for insights into the big questions in precision medicine and clinical research.
This webinar, hosted by Sano CEO Dr. Patrick Short and featuring David Ochoa, Platform Coordinator at Open Targets, explores the significance of human genetics in pinpointing drug targets, the variety of data sets employed, target safety, and methods of intervention. It also touches on the changing nature of drug modalities and prospective avenues for future research.
The relationship between DNA and health is being understood better every day. We now know that our genes affect our risk of disease, symptoms, and even how we react to medications. But with genetic testing becoming a more prominent part of healthcare, genetic counsellors play a vital role in supporting people through the process and helping them understand the results of testing and what it means for them as patients. In this blog, we'll discuss the importance of genetic counsellors and how they bridge the gap between scientific advancement and patient care.
The 21st century heralds a paradigm shift in healthcare and medicine, driven predominantly by the breakthroughs in genetic testing. This blog post explores how genetic testing is redefining the fields of biotechnology and pharmaceuticals, marking a new era of precision medicine. From decoding our DNA to ushering in targeted therapies, genetic testing stands as a cornerstone of modern medical innovation.
Digital twins are virtual models designed to accurately reflect a physical object or system. The concept comes from engineering and has been applied to complex systems such as airplanes, manufacturing, and even cities. While the use of digital twins in healthcare is still very new, it is already showing promise for more personalised treatments and creating a better understanding of patient health.
While lifestyle choices and environment can impact risk, genes are often what most affect how likely a person is to develop a disease. People commonly have different versions of a gene throughout a population, and some of these versions are associated with an increase in disease risk. Polygenic risk scores consider these gene variations and can provide a measurement of a person's risk for a specific disease.
Clinical trials are the cornerstone of medical advancements, allowing researchers to develop new treatments, therapies, and medications. However, a critical challenge in conducting successful clinical trials is patient recruitment. Efficient patient recruitment ensures that trials progress smoothly, providing results that benefit both the medical community and patients. To overcome this challenge, clinical trial patient recruitment companies and platforms play a vital role. In this blog, we’ll examine the world of clinical trial patient recruitment, exploring the role of various vendors and platforms.
Clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated protein (Cas) systems are programmable genome editing tools that can mediate site-specific DNA modifications. Although gene-editing technologies, including CRISPR, enable highly specific treatments tailored to individuals, their clinical success depends on overcoming issues like efficiency, gene correction specificity, and precise cell targeting. Here, we'll discuss the potential gene-editing technologies like CRISPR have for personalised therapies, as well as the challenges and regulatory landscape that affect its clinical uptake.
The development of NASH, the advanced stage of nonalcoholic fatty liver disease, is a complex interplay of genetic and environmental factors. Genes like PNPLA3, TM6SF2, GCKR, MBOAT7, and HSD17B13 play pivotal roles in NASH susceptibility. Lifestyle factors, particularly diet and exercise, amplify the genetic influence on NASH risk.
Pharmacogenomics, also known as pharmacogenetics, is a field of research dedicated to investigating how an individual's genetic makeup influences their response to medications.
This webinar, hosted by Sano CEO Dr. Patrick Short and featuring Dr. Dimitar Tonev, an expert in liver disease and hepatology, sheds light on the latest developments in liver disease – particularly non-alcoholic steatohepatitis (NASH) – including significant changes and predictions for the future.